Maxim Group Thinks Nephros’ Stock is Going to Recover

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Nephros (NEPHResearch Report), with a price target of $10.00. The company’s shares closed last Thursday at $2.53, close to its 52-week low of $2.48.

According to TipRanks.com, Vendetti is a 3-star analyst with an average return of 1.0% and a 34.2% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, Applied DNA Sciences, and ReShape Lifesciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nephros with a $7.63 average price target, implying a 163.1% upside from current levels. In a report issued on May 2, B.Riley Financial also maintained a Buy rating on the stock with a $8.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $11.67 and a one-year low of $2.48. Currently, Nephros has an average volume of 38.62K.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NEPH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Nephros, Inc. is a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system. The company operates in two segments: Water Filtration and Renal Products. The Water Filtration segment includes both the medical device and commercial filtration product lines. The Renal Products segment comprises of SRP, which is focused on the development of medical device products for patients with renal disease, including a second-generation HDF system for the treatment of patients with ESRD. Its ultrafilters are used in dialysis centers for the removal of biological contaminants from water, bicarbonate concentrate and blood. The company was founded on April 3, 1997 and is headquartered in South Orange, NJ.

Read More on NEPH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More